Back to today’s briefing

Story perspectives

FDA Approves Epioxa: Breakthrough Keratoconus Treatment Coming 2026

10/22/2025

37 3

Summary

Story summary

Glaukos Corporation announced FDA approval of Epioxa, a topical therapy for keratoconus.
Epioxa is an incision-free treatment that does not remove the corneal epithelium.
The therapy is bioactivated by UV light and aims to improve patient comfort.
Approval rests on two Phase 3 trials with over 400 patients showing favorable safety and efficacy.
Epioxa is expected to be commercially available in early 2026.

1 of 1

Story summary

Glaukos Corporation announced FDA approval of Epioxa, a topical therapy for keratoconus.
Epioxa is an incision-free treatment that does not remove the corneal epithelium.
The therapy is bioactivated by UV light and aims to improve patient comfort.
Approval rests on two Phase 3 trials with over 400 patients showing favorable safety and efficacy.
Epioxa is expected to be commercially available in early 2026.